Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ECE1 | P42892 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.34 |
| ▸ | PGK1 | P00558 | 1/20 | 0.34 |
| ▸ | PGK2 | P07205 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523329 | 1.00 | LTA4H (0.35) | LTA4HMMEECE1FOLH1PGK1 | |
| SCHEMBL13541669 | 0.84 | MME (0.34) | LTA4HMMEMMP1MMP8TSHR | |
| SCHEMBL3099206 | 0.80 | ANPEP (0.35) | MMP1MMP8TDP1 | |
| SCHEMBL3099197 | 0.80 | ANPEP (0.35) | MMP1MMP8TDP1 | |
| SCHEMBL14502966 | 0.78 | MEP1B (0.37) | ECE1MMP1MMP8 | |
| SCHEMBL2991217 | 0.78 | SMN1; SMN2 (0.36) | MMEECE1 | |
| SCHEMBL7763537 | 0.78 | MEP1B (0.37) | ECE1MMP1MMP8 | |
| SCHEMBL2991220 | 0.78 | SMN1; SMN2 (0.36) | MMEECE1 | |
| SCHEMBL11799913 | 0.78 | MME (0.33) | MMEECE1FOLH1PGK1PGK2 | |
| SCHEMBL14502982 | 0.78 | SMN1; SMN2 (0.36) | MMEECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240317780-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2024-09-26 | — | — | US | claimed |
| EP-4337270-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2024-03-20 | — | — | EP | claimed |
| CN-117320759-A | Radiopharmaceutical somatostatin receptor ligands and precursors thereof | 慕尼黑工业大学 | 2023-12-29 | — | — | CN | claimed |
| WO-2022238553-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-11-17 | — | — | WO | claimed |
| US-7776844-B2 | N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use | YU RUEY J | 2010-08-17 | — | — | US | claimed |
| US-20090208499-A1 | N-(Phosphonoalkyl)-Amino Acids, Derivatives Thereof and Compositions and Methods of Use | YU RUEY J | 2009-08-20 | — | — | US | claimed |
| US-7572776-B2 | N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use | YU RUEY J | 2009-08-11 | — | — | US | claimed |
| JP-2009526755-A | — | — | 2009-07-23 | — | — | JP | claimed |
| US-20080306025-A1 | N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE | YU RUEY J | 2008-12-11 | — | — | US | claimed |
| EP-1979366-A2 | N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE | Yu, Ruey J. (US) | 2008-10-15 | — | — | EP | claimed |
| US-7429575-B2 | N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use | YU RUEY J | 2008-09-30 | — | — | US | claimed |
| WO-2007082206-A2 | N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE | YU RUEY J (US) | 2007-07-19 | — | — | WO | claimed |
| US-20070161543-A1 | N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE | YU RUEY J | 2007-07-12 | — | — | US | claimed |
| US-20250313579-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | Technische Universität München (DE) | 2025-10-09 | — | — | US | disclosed |
| US-20240317780-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2024-09-26 | — | — | US | disclosed |
| CN-118201644-A | Ligand compounds comprising chelating groups as bridging groups | 慕尼黑工业大学 | 2024-06-14 | — | — | CN | disclosed |
| WO-2007082206-A2 | N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE | YU RUEY J (US) | 2007-07-19 | — | — | WO | disclosed |
| US-20070161543-A1 | N-(PHOSPHONOALKYL)-AMINO ACIDS, DERIVATIVES THEREOF AND COMPOSITIONS AND METHODS OF USE | YU RUEY J | 2007-07-12 | — | — | US | disclosed |
| US-4654429-A | Process for the preparation of a glyphosate product | MONSANTO COMPANY (US) | 1987-03-31 | — | — | US | disclosed |
| US-4617415-A | α-Substituted N-phosphonomethyliminodiacetic acid | MONSANTO COMPANY (US) | 1986-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317780-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | SSTR1, SSTR3, SSTR4 | LTA4H 4059/4885MME 660/4885ECE1 953/4885 |
| US-20250313579-A1 | LIGAND COMPOUNDS COMPRISING A CHELATING GROUP AS A BRIDGING GROUP | SHBG, SLC40A1, TFRC | LTA4H 3347/4885MME 587/4885ECE1 841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.